Xenon Pharmaceuticals (XENE) Operating Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Operating Expenses data on file, last reported at -$3.1 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at -$3.1 million, down 103.89% year-over-year; the trailing twelve-month figure through Mar 2026 was -$83.7 million (down 157.16% YoY), and the FY2025 annual result was -$332000.0, up 89.02% from the prior year.
• Operating Expenses improved to -$3.1 million in Q1 2026 per XENE's latest filing, from -$271.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $96.3 million in Q3 2025 and troughed at -$271.1 million in Q4 2025.
• A 5-year average of $3.8 million and a median of $30.9 million in 2022 frame the typical range for Operating Expenses.
• On a YoY basis, Operating Expenses climbed as much as 32650.2% in 2025 and fell as far as 11340.3% in 2025.
• A 5-year view of Operating Expenses shows it stood at -$90.3 million in 2022, then sank by 82.05% to -$164.4 million in 2023, then soared by 98.56% to -$2.4 million in 2024, then slumped by 11340.3% to -$271.1 million in 2025, then jumped by 98.85% to -$3.1 million in 2026.
• Business Quant data shows XENE's Operating Expenses at -$3.1 million in Q1 2026, -$271.1 million in Q4 2025, and $96.3 million in Q3 2025.